Saroglitazar is under clinical development by Zydus Therapeutics and currently in Phase II for Metabolic Dysfunction-Associated Steatohepatitis (MASH). According to GlobalData, Phase II drugs for ...

Let's catch up on the latest news from the stock market. From significant investments to major deals, quarterly earnings, order wins and acquisitions, here’s a quick look at which stocks will be ...

Zydus Lifesciences Ltd on Thursday said it has received final approval from the US health regulator to manufacture its generic version of Paliperidone extended-release tablets, used to treat ...

The trend is also visible in other FMCG companies. Zydus Wellness, the company behind brands like Complan and Glucon-D, is expanding its rural coverage, focusing on increasing penetration where brands ...

Trastuzumab emtansine (T-DM1) demonstrates sustained improvement in invasive disease-free survival and reduced the risk for death in human epidermal growth factor receptor 2 (HER2)-positive breast ...

At seven-years follow up, invasive disease-free survival was 80.8% with adjuvant T-DM1 and 67.1% with adjuvant trastuzumab alone. Overall survival was 89.1% with T-DM1 and 84.4% with trastuzumab ...

The primary analysis of KATHERINE, a phase 3, open-label trial, showed that the risk of invasive breast cancer or death was 50% lower with adjuvant trastuzumab emtansine (T-DM1) than with ...

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...

January 15, 2025--(BUSINESS WIRE)--Stoke Space, the rocket company building the world’s first 100% reusable medium-lift rocket, announced today that it has raised $260 million in new Series C ...

The St. Louis Cardinals talked a big game heading into the offseason, saying they were going to embark on a "reset", cutting payroll and giving opportunities to young players. However, the ...

Adjuvant therapy with trastuzumab emtansine has shown improved outcomes. New research findings are summarized in a short video.